RefBan

Referral Banners

Yashi

Thursday, December 19, 2013

Reuters Health Report

Click to View in Browser
12/19/2013
Reuters Election 2012 Daily round-up of the day's top news from the campaign trail, the White House and all the politics in between
New York City Council mulls adding e-cigarettes to smoking ban
NEW YORK (Reuters) - The New York City Council on Thursday will vote on a bill that would add electronic cigarettes to the city's strict smoking ban, in the latest of many anti-tobacco measures signed by outgoing Mayor Michael Bloomberg.
Sanofi to tap ACC registry for cardiovascular clinical trial
PARIS (Reuters) - French drug maker Sanofi and its U.S. partner Regeneron are collaborating with the American College of Cardiology (ACC) to identify patients for clinical trials on alirocumab, their new cholesterol treatment and potential blockbuster.
Amgen cholesterol drug succeeds in late-stage trial
(Reuters) - Amgen Inc said its closely watched experimental cholesterol drug succeeded in reducing the level of bad cholesterol in the blood, compared to a placebo, in a late-stage trial.
French watchdog fines Merck, Reckitt in Subutex generics dispute
PARIS (Reuters) - The French competition authority said on Thursday it had fined Schering-Plough, now owned by Merck, 15.3 million euros ($21 million) over what it called a smear campaign against generic competition to Subutex, its drug for opioid addiction.
In healthcare experiment, patients pay more for 'bad' medicine
NEW YORK (Reuters) - When Tanner Martin, 17, developed excruciating back pain last year, he was sure he needed an X-ray to find out what was wrong. So was his mother, who worried that the pain might indicate a serious injury that could cause permanent disability.
Vertex's cystic fibrosis drug misses goal but helps some adults
(Reuters) - Vertex Pharmaceuticals Inc said on Thursday that ivacaftor, an experimental drug to treat cystic fibrosis, failed to meet its targeted treatment goal in a late-stage study in people aged 6 and older with the "R117H" gene mutation.
Alimera, pSivida to seek eye treatment approval again, shares soar
(Reuters) - pSivida Corp and Alimera Sciences Inc said they would try a fourth time to get approval for an eye treatment for diabetes patients, sending the shares of both companies soaring.
'Superbug' bacteria widespread in U.S. chicken: consumer group
WASHINGTON (Reuters) - About half of the raw chicken breasts in a nationwide sampling carried antibiotic-resistant "superbug" bacteria, a U.S. consumer group said on Thursday, calling for stricter limits on use of the medicines on livestock.
Some Obamacare shoppers can pay January 10 for January 1 coverage
(Reuters) - Individuals who select their health insurance plan on the exchanges set up under the national healthcare reform law by the December 23 deadline will have until January 10 to pay and still receive coverage as of January 1, 2014, the nation's largest organization of insurers said on Wednesday.
Taking HIV prevention pill may not encourage risky sex: U.S. study
CHICAGO (Reuters) - Taking a pill as a preventive measure against HIV infection may not encourage people at high risk for the disease to engage in risky sexual behavior, according to a new U.S. study meant to address fears about its use.
Related Video
Sea Shepherd ships prepare for departure
Snow blasts U.S. Northeast
SUBSCRIBE TO OTHER REUTERS NEWSLETTERS
 Reuters Deals Today
The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today  
Reuters Business Today
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today  
» MORE NEWSLETTERS
- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters
Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details
Subscribe to other Reuters newsletters.
Unsubscribe from this newsletter.
Follow us on Twitter facebook Friend us on Facebook Forward this newsletter to a friend Forward to a friend

No comments:

Yashi

Chitika